An investigation of the inhibitory effects of dendrosomal nanocurcumin on Candida albicans and systemic candidiasis in BALB/c mice
- PMID: 28681006
- PMCID: PMC5490291
- DOI: 10.18869/acadpub.cmm.2.1.7
An investigation of the inhibitory effects of dendrosomal nanocurcumin on Candida albicans and systemic candidiasis in BALB/c mice
Abstract
Background and purpose: Use of curcumin, as a promising antifungal agent, is considered an alternative treatment for fungal infections; however, the low solubility of this agent limits its efficacy. Accordingly, in this study, we aimed to evaluate the in vitro and in vivo antifungal activities of dendrosomal nanocurcumin with improved solubility and bioavailability.
Materials and methods: The in vitro antifungal activities of several Candida species, including C. albicans, C. tropicalis, C. krusei, C. parapsilosis , and C. dubliniensis, were evaluated, using the broth microdilution method. In the in vivo study, different doses of nanocurcumin (5, 10, 20, and 40 mg/kg) were administered to mice with systemic C. albicans infection via intraperitoneal injection. All mice were euthanized at 20 days following the administration of different doses of nanocurcumin. Different organs were extracted for organ culture and histopathological investigation.
Results: Based on the findings, 40 mg/kg of nanocurcumin significantly decreased the fungal load in the evaluated organs; the results were confirmed with histopathological examination. The kidney was found to be the most affected organ with the highest number of severe lesions. Yeasts and pseudohyphae were observed in the blood vessels, kidney, and brain. Also, yeasts were present in the liver, brain, lungs, and heart of the control group.
Conclusion: Although curcumin is generally an excellent antifungal component, its nano-sized form showed more potent properties. Based on the gathered data, dendrosomal nanocurcumin is an effective antifungal agent with good efficacy against disseminated candidiasis. However, further studies are required to evaluate the effects of dendrosomal nanocurcumin on other fungal infections. Also, this agent could be useful for the prevention of fungal infections, such as candidiasis, particularly in high-risk patients.
Keywords: Antifungal; Candida albicans; Nanocurcumin; Systemic candidiasis.
Conflict of interest statement
The authors declare no conflicts of interest.
Similar articles
-
Curcumin nanoparticles: the topical antimycotic suspension treating oral candidiasis.Odontology. 2023 Apr;111(2):350-359. doi: 10.1007/s10266-022-00742-4. Epub 2022 Sep 13. Odontology. 2023. PMID: 36100802 Free PMC article.
-
Candida and candidaemia. Susceptibility and epidemiology.Dan Med J. 2013 Nov;60(11):B4698. Dan Med J. 2013. PMID: 24192246 Review.
-
Experimental systemic virulence of oral Candida dubliniensis isolates in comparison with Candida albicans, Candida tropicalis and Candida krusei.Mycoses. 2011 Sep;54(5):e278-85. doi: 10.1111/j.1439-0507.2010.01899.x. Epub 2010 May 19. Mycoses. 2011. PMID: 20492535
-
[Antifungal susceptibility profiles of Candida species to triazole: application of new CLSI species-specific clinical breakpoints and epidemiological cutoff values for characterization of antifungal resistance].Mikrobiyol Bul. 2016 Jan;50(1):122-32. doi: 10.5578/mb.10682. Mikrobiyol Bul. 2016. PMID: 27058336 Turkish.
-
Non-albicans Candida spp. causing fungaemia: pathogenicity and antifungal resistance.J Hosp Infect. 2002 Apr;50(4):243-60. doi: 10.1053/jhin.2001.1151. J Hosp Infect. 2002. PMID: 12014897 Review.
Cited by
-
Curcumin nanoparticles: the topical antimycotic suspension treating oral candidiasis.Odontology. 2023 Apr;111(2):350-359. doi: 10.1007/s10266-022-00742-4. Epub 2022 Sep 13. Odontology. 2023. PMID: 36100802 Free PMC article.
-
Antifungal Activity of Curcuminoids and Difluorinated Curcumin Against Clinical Isolates of Candida Species.Adv Exp Med Biol. 2021;1328:123-129. doi: 10.1007/978-3-030-73234-9_8. Adv Exp Med Biol. 2021. PMID: 34981474
References
-
- Enoch DA, Ludlam HA, Brown NM. Invasive fungal infections: a review of epidemiology and management options. J Med Microbiol. 2006;55(Pt 7):809–18. - PubMed
-
- Sardi JC, Scorzoni L, Bernardi T, Fusco-Almeida AM, Mendes Giannini MJ. Candida species: current epidemiology, pathogenicity, biofilm formation, natural antifungal products and new therapeutic options. J Med Microbiol. 2013;62(Pt 1):10–24. - PubMed
-
- Eggimann P, Garbino J, Pittet D. Epidemiology of Candida species infections in critically ill non-immunosuppressed patients. Lancet Infect Dis. 2003;3(11):685–702. - PubMed
-
- Liguori G, Di Onofrio V, Galle F, Lucariello A, Albano L, Catania MR, et al. Candida albicans identification: comparison among nine phenotypic systems and a multiplex PCR. J Prev Med Hyg. 2010;51(3):121–4. - PubMed
-
- Dovigo LN, Pavarina AC, Carmello JC, Machado AL, Brunetti IL, Bagnato VS. Susceptibility of clinical isolates of Candida to photodynamic effects of curcumin. Lasers Surg Med. 2011;43(9):927–34. - PubMed
LinkOut - more resources
Full Text Sources
Other Literature Sources